Edwards Lifesciences Co. (NYSE:EW) Shares Bought by OLD National Bancorp IN

OLD National Bancorp IN grew its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 1.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 186,450 shares of the medical research company’s stock after purchasing an additional 2,299 shares during the quarter. OLD National Bancorp IN’s holdings in Edwards Lifesciences were worth $14,217,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Nordea Investment Management AB lifted its stake in shares of Edwards Lifesciences by 1,224.1% in the fourth quarter. Nordea Investment Management AB now owns 1,610,412 shares of the medical research company’s stock worth $123,261,000 after acquiring an additional 1,488,791 shares in the last quarter. Telos Capital Management Inc. lifted its stake in shares of Edwards Lifesciences by 158.2% in the fourth quarter. Telos Capital Management Inc. now owns 91,405 shares of the medical research company’s stock worth $6,970,000 after acquiring an additional 56,000 shares in the last quarter. Arlington Trust Co LLC lifted its stake in shares of Edwards Lifesciences by 5,092.4% in the fourth quarter. Arlington Trust Co LLC now owns 12,306 shares of the medical research company’s stock worth $938,000 after acquiring an additional 12,069 shares in the last quarter. Versor Investments LP lifted its stake in shares of Edwards Lifesciences by 83.3% in the third quarter. Versor Investments LP now owns 4,496 shares of the medical research company’s stock worth $311,000 after acquiring an additional 2,043 shares in the last quarter. Finally, HealthInvest Partners AB bought a new stake in Edwards Lifesciences in the fourth quarter valued at about $1,587,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on EW. Citigroup boosted their price objective on Edwards Lifesciences from $90.00 to $98.00 and gave the company a “neutral” rating in a report on Wednesday, April 3rd. OTR Global raised Edwards Lifesciences from a “mixed” rating to a “positive” rating in a report on Tuesday, March 26th. StockNews.com lowered Edwards Lifesciences from a “buy” rating to a “hold” rating in a report on Wednesday, March 20th. Bank of America raised Edwards Lifesciences from a “neutral” rating to a “buy” rating in a report on Thursday, March 7th. Finally, Stifel Nicolaus upped their target price on Edwards Lifesciences from $70.00 to $83.00 and gave the company a “hold” rating in a report on Wednesday, February 7th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and ten have given a buy rating to the company. According to MarketBeat, Edwards Lifesciences currently has an average rating of “Moderate Buy” and a consensus price target of $91.73.

Insiders Place Their Bets

In other news, VP Jean-Luc M. Lemercier sold 14,400 shares of the stock in a transaction on Monday, April 8th. The stock was sold at an average price of $92.32, for a total transaction of $1,329,408.00. Following the completion of the sale, the vice president now owns 173,849 shares in the company, valued at approximately $16,049,739.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, VP Jean-Luc M. Lemercier sold 14,400 shares of the stock in a transaction on Monday, April 8th. The stock was sold at an average price of $92.32, for a total transaction of $1,329,408.00. Following the completion of the sale, the vice president now owns 173,849 shares in the company, valued at approximately $16,049,739.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 11,000 shares of the stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $85.83, for a total value of $944,130.00. Following the sale, the vice president now owns 39,503 shares of the company’s stock, valued at approximately $3,390,542.49. The disclosure for this sale can be found here. Insiders sold 194,004 shares of company stock worth $17,166,254 over the last ninety days. Company insiders own 1.29% of the company’s stock.

Edwards Lifesciences Price Performance

EW traded down $0.51 during trading on Friday, reaching $85.94. The stock had a trading volume of 3,895,701 shares, compared to its average volume of 2,826,513. The firm has a market capitalization of $51.73 billion, a price-to-earnings ratio of 37.37, a price-to-earnings-growth ratio of 4.26 and a beta of 1.05. The company has a quick ratio of 2.40, a current ratio of 3.38 and a debt-to-equity ratio of 0.09. Edwards Lifesciences Co. has a 1-year low of $60.57 and a 1-year high of $96.12. The stock has a 50 day moving average of $90.15 and a two-hundred day moving average of $78.37.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Tuesday, February 6th. The medical research company reported $0.64 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.64. The firm had revenue of $1.53 billion during the quarter, compared to the consensus estimate of $1.50 billion. Edwards Lifesciences had a return on equity of 23.56% and a net margin of 23.35%. The firm’s revenue for the quarter was up 13.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.64 earnings per share. As a group, equities analysts anticipate that Edwards Lifesciences Co. will post 2.76 EPS for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.